Research
Publications
CFAR-DS researchers produce cutting-edge findings which are published in national and international journals. You can find a selection of published works below.
2023
Weight Loss and Alzheimer’s Disease in Down Syndrome. J Alzheimers Dis. 2023. Alzheimer’s Biomarker Consortium –Down Syndrome (ABC-DS) Consortium. CFAR-DS Authors: Head and Mapstone.
Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer’s disease: a cross-sectional study. Lancet Neurol. 2023. CFAR-DS Authors: Head and Mapstone.
Past Publications
2022
- Longitudinal Analysis of the Microbiome and Metabolome in the 5xfAD Mouse Model of Alzheimer’s Disease. mBio. 2022. CFAR-DS Author: Mapstone.
- Amyloid futures in the expanding pathology of brain aging and dementia. Alzheimers Dement. 2022. CFAR-DS Author: Head.
- Reduced synaptic proteins and SNARE complexes in Down syndrome with Alzheimer’s disease and the Dp16 mouse Down syndrome model: Impact of APP gene dose. Alzheimers Dement. 2022. CFAR-DS Author: Head.
- Aβ and tau prions feature in the neuropathogenesis of Down syndrome. Proc Natl Acad Sci U S A. 2022. CFAR-DS Author: Head.
- Blood pressure variability and plasma Alzheimer’s disease biomarkers in older adults. Sci Rep. 2022. CFAR-DS Author: Head.
- Primitive Reflexes and Dementia in Adults With Down Syndrome. Neurol Clin Pract. 2022.
Research Studies
CFAR-DS is one site of the national ABC-DS study, but also supports multiple other studies.
The NIH INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) Project was launched in June 2018 in support of a Congressional directive in the fiscal year (FY) 2018 Omnibus Appropriations. The directive called for a new trans-NIH research initiative on critical health and quality-of-life needs for individuals with Down syndrome
The Trial-Ready Cohort-Down Syndrome (TRC-DS) matches people with Down syndrome to clinical trials related to Alzheimer’s disease. TRC-DS routinely monitors study participants for any changes to their brain health or function over time through blood tests and brain imaging to eventually match them with applicable Alzheimer’s disease clinical trials. Because participants are routinely evaluated, researchers can fast-track them for enrollment into qualifying clinical studies as soon as they are eligible and matched with one.
UCI CFAR-DS DiscoverieS Video Series
The UCI CFAR-DS DiscoverieS Series – Interviewing Researchers at the Forefront of Aging in DS Discovery
